Compare ELDN & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELDN | INO |
|---|---|---|
| Founded | 2004 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.6M | 118.9M |
| IPO Year | 2014 | 1999 |
| Metric | ELDN | INO |
|---|---|---|
| Price | $2.69 | $1.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 900.4K | 719.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.27 | 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $23,060.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $1.35 | $1.30 |
| 52 Week High | $4.60 | $2.86 |
| Indicator | ELDN | INO |
|---|---|---|
| Relative Strength Index (RSI) | 58.67 | 46.88 |
| Support Level | $2.48 | $1.48 |
| Resistance Level | $2.77 | $1.78 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 54.23 | 8.39 |
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.